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Abstract
Background: Chronic Obstructive Pulmonary Disease (COPD) is characterized by an excessive activation of the
adaptive immune system and, in particular, uncontrolled expansion of the B-cell pool. One of the key promoters
of B cell expansion is A PRoliferation-Inducing Ligand (APRIL). APRIL has been strongly linked to non small cell lung
cancer (NSCLC) onset and progression previously. However, little is known about the expression of APRIL in the
lungs of COPD patients.
Methods: Using immuno-fluorescence staining, the expression of APRIL was assessed in sections of lungs from
4 subjects with primary diagnosis of COPD (FEV1 33 ± 20 % predicted), 4 subjects with primary diagnosis of NSCLC,
4 subjects diagnosed with both COPD and NSCLC, smokers without COPD or NSCLC and 3 healthy never-smokers.
The percentage of B cells, alveolar macrophages (AMs) and polymorphonuclear neutrophils (PMNs) in the lung and
alveolar epithelial cells (AECs) that stained positively for APRIL was quantified using epi-fluorescence microscopy
and image analysis software.
Results: The percentage of APRIL-expressing B cells, AMs, PMNs and alveolar epithelial cells (AECs) was higher in
patients having both COPD and NSCLC than in patients with either COPD or NSCLC alone, SC or NSC (p < 0.03 for
all comparisons). The percentage of APRIL-expressing AMs and AECs (but not in B cells) was higher in patients with
NSCLC alone than in patients with COPD alone. The percentage of APRIL-expressing AECs (but not B cells or AMs)
was higher in COPD patients than in SC and NSC (p < 0.05 for all comparisons). The percentage of APRIL-expressing
B cells, AMs and AECs cells was similar in NSC and SC.
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Conclusion: The percentage of APRIL-expressing B cells, AMs and AECs is higher in the lungs of patients with both
COPD and NSCLC than in patients with COPD or NSCLC alone or control subjects. These findings suggest that
APRIL may contribute to the pathogenesis of both COPD and NSCLC, and possibly to the development of NSCLC in
patients with established COPD.
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Background
Chronic obstructive pulmonary disease (COPD) is
characterized by an enhanced pulmonary and systemic
inflammatory response to inhaled particles and gases,
particularly those found in tobacco smoke. COPD patients
have an increased risk of developing non-small cell lung
cancer (NSCLC) that is independent of smoking pack-year
history [1, 2]. However, the factors that promote the devel-
opment of NSCLC in COPD patients are not clear. React-
ive oxygen and nitrogen species (ROS and RNS) derived
from both exogenous and endogenous sources drive many
of the pathways in both COPD and lung cancer [3]. ROS
and RNS can react directly with DNA causing DNA dam-
age, or impair DNA repair processes [4]. Increased lung
oxidative stress levels can also increase the susceptibility
of COPD patients to recurrent respiratory tract infections,
and drive chronic inflammation in the lungs, leading to
further DNA damage and cellular injury by inducing the
production of cytokines and proteinases in the lung [5].
Injury to the lungs that is induced by chronic inflamma-
tion triggers repair processes including cellular prolifera-
tion which, together with ROS and RNS-induced DNA
damage, may promote tumorigenesis.
Both innate immune cells (such as PMNs and alveolar
macrophages [AMs]) and adaptive immune cells (T and
B lymphocytes) participate in the chronic inflammatory
responses occurring in COPD lungs [6–10]. This process
does not resolve after cessation of smoking, suggesting
that self-perpetuating mechanism(s) (similar to those oc-
curring in autoimmune disease [8, 11]) are involved. This
autoimmune response likely involves activation of (auto re-
active) B cells [12] as the number of B cells in small airways
is increased in severe and very severe COPD [13]. In
contrast to COPD, there is a negative correlation between
the severity of T lymphocyte infiltration in the lung and
NSCLC disease progression [14–16]. As well as in COPD
patients, NSCLC patients have tertiary lymphoid structures
(TLS) characterized by clusters of mature dendritic cells
and T cells surrounded by B cells, and all stages of B-cell
differentiation are detectable in most NSCLC tumors [17].
A high density of follicular B cells correlates with long-term
survival, both in patients with early-stage NSCLC and with
advanced-stage NSCLC treated with chemotherapy [17].
However, IL-10-producing immunosuppressive regulatory
B cells are also increased in NSCLC, and their numbers
correlate directly with disease progression [18]. Thus, the
roles of B cells (and their subsets) in regulating the develop-
ment of NSCLC remains unclear.
Regulation of B-cell homeostasis involves two members of
the TNF-alpha family: B-cell Activating Factor (BAFF) and
A proliferation-inducing ligand (APRIL, TNFSF13, TRDL-1,
TNF-related death ligand-1), which share two receptors
(B-cell maturation antigen (BCMA) and transmembrane
activator and calcium-modulator and cyclophilin ligand
interactor (TACI). A third receptor, the BAFF receptor, only
binds to BAFF [19]. BAFF and APRIL are key regulators of
the immune response and are produced by myeloid leuko-
cytes, lymphocytes and epithelial cells [20–25]. BAFF and
APRIL both promote peripheral B-cell survival, maturation,
and differentiation and play important roles in the produc-
tion of antibodies. Serum levels of BAFF and APRIL are
increased in several autoimmune diseases [26, 27].
APRIL is a type II membrane protein and a soluble
form is produced by several cells [28]. APRIL expression
is upregulated at the transcript and protein levels in
NSCLC tumor cells and stromal fibroblasts [29, 30].
High-level expression of ARRIL in stromal cells was associ-
ated with impaired differentiation of stromal cells, and
APRIL expression levels in tumor cells are an independent
prognostic factor for 5-year survival in patients with
NSCLC [30]. While some studies report that APRIL pro-
motes the growth of some tumor cells [31], other studies
report that APRIL promotes apoptosis of other tumor cell
types [32, 33]. However, nothing is known about the
expression of APRIL in immune cells or lung epithelial cells
in NSCLC patients. Also, it is not clear whether the expres-
sion of APRIL is altered in the lungs of COPD patients or
patients having both COPD and NSCLC. Herein, we sought
to address these knowledge gaps by measuring APRIL
expression in lung sections from patients with primary diag-
nosis of COPD or NSCLC, patients with both COPD and
NSCLC, smokers without lung disease and never-smokers.
We also identified the leukocyte subsets and lung epithelial
cell types that express this molecule in these diseases.
Methods
Subjects and ethics
Lung tissue cohort characteristics
All studies conducted on human subjects were approved by
the Partners Institutional Review Board. The characteristics
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of the lung tissue cohort studied are shown in Fig. 1. De-
identified sections of lung were obtained from lung biop-
sies, or from lung explants from COPD patients provided
by NHLBI-sponsored Lung Tissue Research Consortium
(www.ltrcpublic.com), or the Department of Pathology at
Brigham and Women’s Hospital, Boston. None of the sub-
jects studied had evidence of respiratory tract infection at
the time of lung tissue sampling. Among the subjects stud-
ied, 8 subjects had a primary diagnosis of COPD (forced
expiratory volume in 1 s/forced vital capacity [FEV1/FVC]
< 0.7), 4 subjects had a primary diagnosis of NSCLC, 3 were
healthy ever-smokers (SC), and 3 were healthy never-
smokers (NSC). Among the COPD patients, 4 had a sec-
ondary diagnosis of NSCLC.
Immunostaining of lung sections for APRIL
Formalin-fixed and paraffin-embedded sections (5 μm
thick) of peripheral lung sections from the subjects were
studied. Lung sections were deparaffinized, and antigen
(Ag) retrieval was performed by boiling the slides
immersed in 0.01 M sodium citrate and 2 mM citrate
buffer (pH 6.0) in a microwave. We used a rabbit anti-
APRIL IgG followed by goat anti-rabbit F(ab’)2 conju-
gated to Alexa-488 to identify APRIL-positive cells.
PMNs were identified by their characteristic multi-lobed
nuclei (identified by counter-staining lung sections with
4′,6-diamidino-2-phenylindole [DAPI]). AMs were de-
fined as mononuclear cells (having ample cytoplasm)
present in the alveolar spaces. Bronchial and alveolar
epithelial cells were identified in bright-field images. To
identify B cells, we immunostained the sections with a
murine anti-CD20 IgG followed by a goat anti-murine
IgG conjugated to Alexa-546. All of the antibodies (Abs)
listed were purchased from Abcam (Cambridge, MA)
and secondary antibodies were obtained from Thermo-
Fisher Scientific (Cambridge, MA). Lung sections were
also immuno-stained with appropriate isotype-matched
non-immune control antibodies. Images of the immuno-
stained lung sections were captured and analyzed using
an epi-fluorescence microscope (Leica Microsystems,
Buffalo Grove, IL).
In order to quantify APRIL expression in PMNs and B
cells, PMNs and B cells in at least 50 non-consecutive
high-magnification fields were analyzed. At least 20
AMs within the alveolar spaces were evaluated for each
patient. Results were expressed as percentage of all
AMs, PMNs and B-cells that were counted that stained
positively for APRIL. For evaluation of APRIL in AECs,
cells in the alveolar walls in 10 non-consecutive high
magnification fields were evaluated for each subject. The
area of the alveolar wall was measured using Meta-
Morph software (Molecular Devices, Sunnyvale, CA).
APRIL-positive cells within the alveolar walls were
counted and the results were expressed as the number
of positive cells/pixel of alveolar wall.
Statistical analyses
Data were analyzed using one-way ANOVA tests for
continuous variables (age, FEV1 % predicted and pack/
years) followed by pair-wise comparisons using student’s
t-tests or Mann-Whitney U tests. The Chi-square test
was used to analyze categorical variables. P < 0.05 was
considered statistically significant.
Fig. 1 The proportion of APRIL-expressing B cells in the lungs of
control subjects, and patients with COPD alone, NSCLC alone or
patients with both COPD and NSCLCs: The percentages of APRIL-
positive B cells in the lungs of NSC, SC, patients with COPD
alone, NSCLC alone and both COPD and NSCLC are shown. The
box plots show the median values and the 5 and 95 % confidence
intervals, and the error bars are the standard deviations. * indicates
p < 0.03 vs. NSC or vs. the group indicated
Fig. 2 The proportion of APRIL-expressing AECs in the alveolar walls
of control subjects, and patients with COPD alone, NSCLC alone or
patients with both COPD and NSCLCs: The percentages of APRIL-
positive AECs in the alveolar walls of NSC, SC, patients with COPD
alone, NSCLC alone and both COPD and NSCLC are shown. The box
plots show the median values and the 5 and 95 % confidence
intervals, and the error bars are the standard deviations. * indicates
p < 0.03 vs. NSC or vs. the group indicated
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Results
Demographics
The demographic characteristics of the patients are
shown in Table 1. NSC, SC, COPD patients and patients
with cancer did not differ in their sex ratios or pack-year
smoking histories. The age of the patients having both
COPD and NSCLC was significantly higher than that of
the patients with COPD alone. The smoking pack-year
histories of the SC, patients with COPD alone or
NSCLC alone were similar, and all were significantly
higher than that of the NSC by design. The pack-year
smoking histories were not available for patients with
COPD and NSCLC. The FEV1 as a percentage of pre-
dicted (FEV1 % pred) was not available for the NSC and
was only available for one of the four patients with both
COPD and NSCLC. In the latter group, COPD was diag-
nosed on the basis of the presence of emphysema in high
resolution computed tomography (HRCT) scans of the
thorax and an FEV1/FVC ratio < 0.7, but the FEV1% pre-
dicted was not available from the electronic medical
records. There was a significant difference in FEV1 % pred
between COPD patients and both SC and NSC by design.
The proportion of APRIL-expressing AMs and B cells is
higher in the lungs of patients with both COPD and
NSCLC versus COPD alone, NSCLC alone or control subjects
APRIL expression was detected in some B cells, AECs
and AMs in lung sections from all subjects studied albeit
at low levels in SC and NSC. No staining was present in
bronchial epithelial cells in any of the subject groups, or
in lung sections stained with non-immune isotype-
matched non-immune antibodies.
The percentage of APRIL-positive B cells was higher in
the lung sections from patients with both COPD and
NSCLC when compared to patients with COPD alone,
NSCLC alone, SC and NSC (Fig. 1; p < 0.005 for all com-
parisons). The percentage of APRIL-positive B cells was
higher in lung sections from patients with NSCLC alone
than in the lungs of SC or NSC (p < 0.03 for both com-
parisons; Fig. 1). The percentage of APRIL-positive B
cells was similar in lung sections from patients with
NSCLC alone versus COPD alone; patients with COPD
alone versus SC and NSC; and also SC versus NSC.
The number of APRIL-expressing AECs is higher in patients
with both COPD and NSCLC versus COPD alone, NSCLC
alone or control subjects
Patients with both COPD and NSCLC had a higher
number of APRIL-positive AECs per area of alveolar
wall than patients with either COPD alone or NSCLC
alone (p < 0.03 for both comparisons; Fig. 2) or SC or
NSC (p < 0.005 for both comparisons; Fig. 2). The
number of APRIL-positive AECs was higher in the
alveolar walls of patients with either COPD alone or
NSCLC alone than in the alveolar walls of SC and
NSC (p < 0.02 for all comparisons; Fig. 2). The num-
bers of APRIL-positive AECs were similar in the
alveolar walls of SC and NSC. No staining for APRIL
was detected in bronchial epithelial cells in lung sections
from any of the subject group studied (data not shown).
The proportion of APRIL-expressing AMs is higher in
patients with both COPD and NSCLC versus COPD
alone, NSCLC alone or control subjects
The percentage of APRIL-positive AMs was higher in
lung sections from patients with both COPD and
NSCLC versus NSCLC alone, COPD alone, SC or NSC
(Fig. 3, p < 0.003 for all comparisons). The percentage of
Table 1 The table shows the demographic and clinical characteristics of the healthy never smokers (NSC), healthy smokers (SC) and
patients with COPD alone, NSCLC alone and both COPD and NSCLC. SC were defined as subjects that were current smokers at the
time of the study or had quit smoking less than 1 year before the lung samples were obtained.
Demographics and clinical characteristics of the subjects
Characteristics NSC (n = 3) SC (n = 3) COPDa (n = 3) COPD + Cancer (n = 3) Cancer (n = 3) Pe
% males 33 33 75 75 0 N.S.
Age (yrs) 65 ± 22 63 ± 15 56 ± 7 75 ± 12 64 ± 9 P = 0.03b
Pack-yr smokingc 0 33 ± 23 45 ± 26 N/A 50 ± 10 P < 0.001
FEV1 (% of predicted)
d N/A 87 ± 11 33 ± 20 61f 61 ± 7 P < 0.05
a All COPD patients had forced expiratory volume in 1 s/forced vital capacity (FEV1/FVC) < 0.7 whereas smokers without COPD and non-smoker controls
had FEV1/FCV > 0.7
b The results for age, pack-year smoking history and FEV1 % predicted, are expressed as mean ± SEM. The age of the patients with both COPD and NSCLC was sig-
nificantly higher than that of the patients with COPD alone
c The pack-year smoking histories of the COPD patients and SC groups were significantly different from those of NSC by design (P < 0.001 for both comparisons).
The pack-yr smoking histories of the patients with COPD alone and NSCLC alone were significantly different from those of the SC and NSC
d The FEV1 % predicted and the FEV1/FVC (not shown) in the COPD group were significantly different from that of the SC and NSC by design (P < 0.05 for
both comparisons)
e Statistical analyses included one-way ANOVA tests for continuous variables (age, FEV1 % predicted and pack/years) followed by pair-wise comparisons using stu-
dent’s t-tests or Mann-Whitney U tests. The Chi-square test was used to analyze categorical variables. P < 0.05 was considered statistically significant
f The FEV1 % predicted in the group of subjects with COPD and NSCLC was available only in 1 out of 4 subjects
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APRIL-positive AMs was higher in patients with NSCLC
alone than in patients with COPD alone or NSC (p <
0.03 for both comparisons; Fig. 3). The percentage of
APRIL-positive AMs was similar in lung sections from
patients with COPD and SC, and also in SC and NSC.
The proportion of APRIL-expressing PMNs is higher in
patients with COPD and NSCLC versus COPD alone, or
NSCLC alone
The percentage of APRIL-positive PMNs was higher in
lung sections from patients with COPD and NSCLC
than in patients with either COPD alone or NSCLC
alone (Fig. 4, p < 0.03 for both comparisons). Although
low-level positive staining for APRIL was detected in
PMNs in lung sections from SC and NSC, we could not
quantify the expression of APRIL in cells from these
subjects due to the very small number of PMNs present
in peripheral lung sections from these subject groups.
Discussion
We report for the first time that there are increases
in numbers of APRIL-expressing leukocytes and AECs
in lungs of patients with either COPD or NSCLC
versus control subjects without these diseases. APRIL-
expressing cells in COPD and NSCLC lungs include B
cells, AMs, PMNs and AECs but not bronchial epithelial
cells. Patients with both COPD and NSCLC had a higher
percentage of APRIL-expressing leukocytes and AECs
than patients with either disease alone. We hypothesize
that increased APRIL expression in leukocytes recruited
to the lung or in AECs is linked to the progression of
both COPD and NSCLC, and possibly also to the
development and progression of NSCLC in patients with
established COPD.
APRIL expression in COPD and NSCLC
To our knowledge, APRIL has never been studied in the
lungs of COPD patients. Prior studies of NSCLC report
that APRIL expression is increased in tumor cells and
stromal cells in the vicinity of the tumors [30]. The
activities of APRIL in regulating NSCLC development and
progression are unclear as APRIL promotes the prolifera-
tion of several tumor cell lines in vitro and in vivo [31] but
promotes apoptosis of other tumor cell types [32, 33].
Interestingly, APRIL expression levels in NSCLC cells are
an independent prognostic factor for 5-year survival in
NSCLC patients [30], suggesting that APRIL expression
promotes the progression of NSCLC tumors. Whether
APRIL expression in leukocytes and/or AECs can serve as
a prognostic marker for either COPD or NSCLC was not
studied herein, but will be the focus of our future studies.
Leukocyte-derived APRIL in COPD and NSCLC
We detected impressive increases in APRIL expression in
B cells, AMs and PMNs in the lungs of patients with either
COPD or NSCLC and even greater increases in APRIL
expression in these leukocytes in the lungs of patients
with both diseases. APRIL is produced by a variety of
Fig. 3 The proportion of APRIL-expressing AMs in the lungs of control
subjects, and patients with COPD alone, NSCLC alone or patients with
both COPD and NSCLC: The percentages of APRIL-positive AMs in the
lungs of NSC, SC, patients with COPD alone, NSCLC alone and both
COPD and NSCLC are shown. The median and 5 and 95 % confidence
intervals are shown in the box plots and the error bars in the
box plots are standard deviations. * indicates p < 0.03 vs. NSC or
vs. the group indicated Fig. 4 The proportion of APRIL-expressing PMNs in the lungs of control
subjects, and patients with COPD alone, NSCLC alone or patients with
both COPD and NSCLC: The percentages of APRIL-positive PMNs in the
lungs of NSC, SC, patients with COPD alone, NSCLC alone and both
COPD and NSCLC are shown. The box plots show the median
values and the 5 and 95 % confidence intervals, and the error
bars are the standard deviations. * indicates p < 0.03 vs. NSC or
vs. the group indicated
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cell types such as macrophages, monocytes, dendritic
cells and T lymphocytes [28, 34]. APRIL secreted by
these cells plays a key role in peripheral B cell survival,
maturation and differentiation [28]. B cells have been
strongly linked to COPD pathogenesis by producing
auto-antibodies that promote an inflammatory response
that injures the alveolar walls [12, 13, 25, 35]. A high
density of follicular B cells correlates with long-term
survival in patients with NSCLC treated with chemo-
therapy [17]. However, IL-10-producing immunosuppres-
sive regulatory B cells are also increased in NSCLC, and
their numbers correlate directly with disease progression
[18]. We did not determine whether APRIL is expressed
in different B cell subsets in the lungs in our study. How-
ever, future studies will determine whether APRIL expres-
sion is increased mainly in regulatory B cells and
promotes the survival of this subset to drive NSCLC
progression.
The activity of APRIL in regulating the functions of
leukocytes other than B cells that have been strongly im-
plicated in the pathogenesis of COPD and NSCLC has
been much less well studied. APRIL is expressed by per-
ipheral blood PMNs from healthy subjects, and APRIL
expression in blood PMNs is increased in patients with
B cell lymphomas and associated with reduced expres-
sion of the apoptosis-inducing ligand TRAIL [36].
However, the expression of APRIL in blood or lung
PMNs in patients with COPD and NSCLC has not been
examined previously. Whether the increased APRIL ex-
pression in PMNs in patients with COPD and NSCLC
leads to alterations in PMN function (including apop-
tosis or survival) that promote disease progression in
COPD or NSCLC will be examined in future studies.
Macrophages from tissues other than the lung are
known to express APRIL when activated with tumor
growth factor beta-β, interleukin 4 and other mediators in
vitro [37, 38]. However, to our knowledge APRIL has not
been reported to be expressed by AMs previously. We
detected low-level APRIL expression in AMs in the lungs
of both NSC and NSC. A greater proportion of AMs from
patients with either COPD or NSCLC expressed APRIL
than cells in control subjects, and an even greater propor-
tion of patients with both diseases expressed this mol-
ecule. APRIL induces activation of macrophage-like cells
lines by activating NF-kB [39] which is an important
pro-inflammatory transcription factor in COPD lungs [40].
Likely, the increased APRIL expression by macrophages
that we detected contributes to macrophage activation and
macrophage-mediated pulmonary injury in COPD lungs.
Interestingly, activation of NF-kB in myeloid cells is crucial
for promoting growth of lung cancer cells in murine
models [41]. Whether macrophage APRIL expression is
linked to disease progression in either COPD or NSCLC is
not clear but will be the focus of our future studies.
APRIL expression by AECs in COPD and NSCLC
Normal bronchial epithelial cells and BEAS2B cell lines
express APRIL at low levels in vitro and expression in-
creases when cells are incubated with double stranded
RNA [24], but APRIL expression by AECs has not been
reported previously. Surprisingly, our study reports that
AECs (but not bronchial epithelial cells) in normal lungs
have detectable (albeit low-level) APRIL expression. A
greater proportion of AECs (but not bronchial epithelial
cells) in patients with either COPD or NSCLC patients
express APRIL, and patients with both diseases had the
highest proportion of APRIL-expressing AECs. APRIL is
expressed in epithelial cells in other organs and may
contribute to pathologies occurring in other diseases.
For example, human intestinal epithelial cells trigger
IgA(2) class switching in B cells recruited to mucosal
follicles by releasing APRIL after sensing bacteria
through Toll-like receptors [42]. Thus, it is possible that
APRIL expressed by AECs in the lungs of patients with
COPD and NSCLC contributes to the progression of
each disease by activating B cells and macrophages in
the lungs (and/or tumor cells in the case of patients with
NSCLC). Whether APRIL regulates the activities of
AECs (such as maintenance of the lung structure, barrier
function and secretion of pro-inflammatory or pro-
angiogenic cytokines, growth factors and host defense
proteins) [43–47] that could contribute to the progression
of COPD or NSCLC is not clear.
Linking APRIL to the development of NSCLC in COPD
patients
Herein, we report for the first time that APRIL expres-
sion was significantly higher in lung leukocytes and
AECs in patients having both COPD and NSCLC, than
in patients with either COPD alone or NSCLC alone. A
common link between COPD and NSCLC is the pres-
ence of chronic pulmonary inflammation consisting of
cells of both innate and adaptive immune systems, as
aberrant inflammation has been proposed as the com-
mon link between these two pathologies [48]. There is
substantial evidence that chronic pulmonary inflamma-
tion promotes the development and progression of
COPD [25, 49, 50]. In NSCLC, there is a marked infiltra-
tion of cells of both innate and adaptive immune system,
and the cell types and their tissue localization are signifi-
cantly associated with progression and survival. As is the
case in COPD patients, NSCLC patients have tertiary
lymphoid structures (TLS) characterized by clusters of
mature dendritic cells and T cells surrounded by B cells
[13, 17]. Leukocytes have both tumor-promoting and
-inhibiting roles [51, 52]. Although we detected increases
in APRIL expression in PMNs and AMs in patients
with NSCLC, the activities of APRIL in regulating
PMN and AM function (such as their activation states,
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survival and ability to removed transformed cells) were
not examined in our study, but will be the focus of future
studies. However, our results raise the intriguing possibil-
ity that increased APRIL expression in lung leukocytes in
COPD patients further activates these cells to produce
more APRIL. This, in turn, could create an environment
conducive to tumorigenesis as reactive oxygen species
released by leukocytes promote formation of reactive car-
bonyls that are not only tumorigenic by initiating DNA
damage [53], but can directly alter the function of regula-
tory proteins involved in host immunity and having tumor
suppressor functions [54]. Leukocytes also release various
growth factors and pro-angiogenic mediators that pro-
mote tumor development [55]. Alternatively, the increased
APRIL expression by AECs in COPD lungs could promote
tumorigenesis by inducing excessive proliferation of bron-
chial epithelial cells. Once NSLC is established in COPD
lungs, the high levels of APRIL produced by leukocytes,
AECs, and/or tumor cells themselves could promote
NSCLC progression as APRIL potently promotes survival
of tumor cells in vitro, and also when human tumors are
transplanted into immune-deficient mice [31].
Limitations of our study
Our study has several limitations. First, we studied a
small number of subjects. Patients with both COPD and
lung cancer were significantly older than those with
COPD alone. Second, in the group of patients with both
COPD and NSCLC, only one out of four patients had
PFT values available, and the pack-year smoking histor-
ies were not available for this group. In the latter group
COPD was diagnosed using HRCT scans and FEV1/FVC
ratios < 0.7 (but the absolute FEV1 and FVC values were
not reported). Thus, we were not able to correlate
APRIL expression with COPD severity, pack-year smok-
ing history, current versus former smoker status or
NSCLC cell type. Another limitation of our study is that
we did not measure the APRIL expression levels per cell
(only the percentage of APRIL-expressing cells). We also
did not correlate APRIL expression with readouts of
cellular functions germane to COPD or NSCLC. These
studies will be the focus of future studies in our laboratory.
Conclusions
Herein, we report an increased APRIL expression in
lung leukocytes and AECs in patients with COPD alone
and NSCLC alone, and even greater increases in these
cells in patients with both diseases. Our results suggest
that exaggerated APRIL expression in lung leukocytes
and/or AECs could create an environment conducive
to the development and/or progression of NSCLC in
patients with COPD.
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